1. Publication
- Title: Impact of magnesium on the clearance of lactate in critically sick patients with sepsis: Randomized clinical trial
- Acronym: None assigned
- Year & Journal: World Journal of Critical Care Medicine, 2026;15(2):115389
- Citation: Anbarasan C, Sharma A, et al. Impact of magnesium on the clearance of lactate in critically sick patients with sepsis: Randomized clinical trial. World J Crit Care Med. 2026;15(2):115389. doi:10.5492/wjccm.v15.i2.115389
2. Context & Rationale
Background: Hypomagnesemia is common in critical illness and has been associated with higher serum lactate and longer ICU/hospital stay in observational data. A prior small RCT (Noormandi et al., 2020, n=58) found magnesium supplementation improved lactate clearance in severe sepsis. This trial is described by its authors as the first to specifically evaluate time to 20% lactate clearance after magnesium supplementation in sepsis.
Research Question/Hypothesis: In critically ill adults with sepsis (Sepsis-3) and lactate >2 mmol/L, does magnesium sulfate supplementation reduce time to 20% lactate clearance compared with placebo?
Why This Matters: Lactate clearance is a widely used resuscitation target in sepsis; if a simple, inexpensive intervention (magnesium) accelerates clearance, it could be an easily deployable adjunct, particularly relevant in hypomagnesemic patients.
3. Design & Methods
- Study Type: Triple-blind, placebo-controlled RCT
- Setting & Centers: Single-center (All India Institute of Medical Sciences); center count not otherwise specified in available trial text
- Population:
- Inclusion: Adults meeting Sepsis-3 criteria with serum lactate >2 mmol/L
- Exclusions: Not reported in available trial text
- Intervention: 2 g magnesium sulfate diluted in 50 mL normal saline, infused over 2 hours, once daily for 3 days (Group M)
- Comparator: Identical-appearing saline placebo (Group P)
- Blinding: Triple-blind (patient, clinician, and outcome assessor/statistician blinded)
- Statistical Power & Follow-Up: 138 adults randomized; follow-up through hospital discharge for length-of-stay outcomes and to 28 days for mortality. Primary analysis population/ITT details not further specified in available trial text.
4. Key Results
Outcome | Magnesium (Group M) | Placebo (Group P) | Effect Size | 95% CI | p-value | Clinical Notes |
Time to 20% lactate clearance (primary) | 5.73 ± 2.19 h | 8.54 ± 2.72 h | Mean difference −2.81 h | −3.65 to −1.99 | <0.001 | Substantially faster clearance with magnesium |
Lactate clearance, day 1 | 18.88% | 12.61% | Not reported | Not reported | Significant (per authors) | Greater increase in clearance with magnesium |
Lactate clearance, day 2 | 30.02% | 23.34% | Not reported | Not reported | Significant (per authors) | — |
Lactate clearance, day 3 | 50.74% | 37.94% | Not reported | Not reported | Significant (per authors) | — |
ICU length of stay | 8 days | 12 days | Not reported | Not reported | Not reported (described as substantial reduction) | — |
Hospital length of stay | 12 days | 16 days | Not reported | Not reported | Not reported (described as substantial reduction) | — |
28-day mortality (secondary) | Numerically lower | — | Not reported | Not reported | Not significant | Authors attribute non-significance partly to single-center design and modest sample size |
Vasopressor dose, days 2–3 | Lower | Higher | Not reported | Not reported | Significant (per authors) | Attributed to magnesium's effect on vascular tone/microcirculation |
5. Internal Validity Assessment
- Randomization & Allocation: Described as randomized; specific sequence-generation and concealment methodology not detailed in available trial text.
- Protocol Adherence & Separation: Not reported in trial text.
- Blinding & Detection Bias: Triple-blind design substantially reduces both performance and detection bias risk for these outcomes.
- Missing Data & Sensitivity Analyses: Not reported in trial text.
- Overall Internal Validity Conclusion: Moderate — rigorous blinding is a strength, but single-center design, modest sample size (n=138), and incompletely reported methodology (randomization concealment, handling of missing data) limit certainty.
6. External Validity Assessment
- Population Representativeness: Single tertiary academic center in India; unclear whether findings generalize to other healthcare settings, sepsis phenotypes, or baseline magnesium status distributions.
- Practice Context: Intervention (IV magnesium sulfate) is inexpensive and widely available, supporting feasibility if benefit is confirmed in larger trials.
- Overall External Validity Conclusion: Limited — single-center trial; broader multicenter replication needed before generalizing.
7. Strengths & Limitations
Strengths:
- Triple-blind design (uncommon rigor for a simple electrolyte intervention trial)
- First trial specifically targeting time-to-20%-lactate-clearance as primary outcome
- Consistent, dose-response-like pattern across days 1–3 clearance measurements
- Corroborates and extends prior smaller RCT (Noormandi et al.)
Limitations:
- Single-center design
- Modest sample size (n=138), underpowered for mortality
- Effect sizes (CIs) for most secondary outcomes not reported in available trial text
- Mortality remains an open question given non-significant, likely underpowered secondary analysis
8. Interpretation & Practice Impact
- Clinical Implications: Supports consideration of magnesium supplementation as an adjunct in septic patients with elevated lactate, particularly given low cost and the triple-blind rigor of this trial, but should not yet be considered practice-changing given single-center, modest-size limitations.
- Mechanistic Coherence: Proposed mechanism (magnesium's effects on vascular tone and microcirculatory perfusion) is biologically plausible and consistent with observed reductions in vasopressor requirement.
- Systems-Level Takeaway: Not yet ready for protocolized order-set inclusion; reasonable candidate for a larger, multicenter confirmatory trial with mortality as a powered primary endpoint.
9. Controversies & Subsequent Evidence
- Editorial Commentary/Debates: Not reported in available trial text.
- Guideline Integration: Not yet incorporated into major sepsis guidelines (e.g., Surviving Sepsis Campaign); this remains an early-stage, single-center signal.
10. Summary & Executive Takeaway
Summary: This triple-blind RCT randomized 138 adults with Sepsis-3-defined sepsis and lactate >2 mmol/L to magnesium sulfate (2g IV daily ×3 days) or placebo. Time to 20% lactate clearance was significantly shorter with magnesium (5.73±2.19h vs 8.54±2.72h; mean difference −2.81h, 95% CI −3.65 to −1.99, P<0.001), with lower vasopressor requirements and shorter ICU/hospital stay, but no significant difference in 28-day mortality.
Overall Takeaway: Magnesium supplementation accelerates lactate clearance and may reduce vasopressor burden and length of stay in sepsis, but this single-center, modestly sized trial was not powered to detect a mortality difference — a signal worth pursuing in a larger multicenter trial before practice adoption.
11. Bibliography
- Noormandi A, Khalili H, Mohammadi M, et al. Effect of magnesium supplementation on lactate clearance in critically ill patients with severe sepsis: a randomized clinical trial. Eur J Clin Pharmacol. 2020;76(2):175-184.